Foamix Pharmaceuticals (NASDAQ:FOMX) Upgraded at ValuEngine

Foamix Pharmaceuticals (NASDAQ:FOMX) was upgraded by ValuEngine from a “sell” rating to a “hold” rating in a report released on Thursday, ValuEngine reports.

A number of other research analysts have also commented on FOMX. Barclays began coverage on shares of Foamix Pharmaceuticals in a research report on Tuesday, June 11th. They set an “overweight” rating and a $10.00 price objective for the company. HC Wainwright set a $12.00 target price on shares of Foamix Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, May 28th. Cantor Fitzgerald reissued a “buy” rating and issued a $15.00 target price on shares of Foamix Pharmaceuticals in a research note on Tuesday, May 7th. Finally, Zacks Investment Research raised shares of Foamix Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $13.96.

Foamix Pharmaceuticals stock traded down $0.06 on Thursday, reaching $2.33. 774,200 shares of the stock were exchanged, compared to its average volume of 354,884. The firm has a market cap of $116.47 million, a PE ratio of -1.37 and a beta of 1.62. Foamix Pharmaceuticals has a twelve month low of $1.97 and a twelve month high of $7.60. The company’s fifty day moving average is $2.39.

Foamix Pharmaceuticals (NASDAQ:FOMX) last announced its quarterly earnings data on Tuesday, May 7th. The specialty pharmaceutical company reported ($0.28) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.24) by ($0.04). The company had revenue of $0.31 million for the quarter, compared to analyst estimates of $0.95 million. Foamix Pharmaceuticals had a negative net margin of 2,115.11% and a negative return on equity of 79.46%. Equities analysts forecast that Foamix Pharmaceuticals will post -1.61 EPS for the current fiscal year.

In related news, Director Anna Kazanchyan sold 10,600 shares of the company’s stock in a transaction dated Monday, May 20th. The shares were sold at an average price of $2.61, for a total value of $27,666.00. Following the sale, the director now owns 55,955 shares of the company’s stock, valued at $146,042.55. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In the last three months, insiders sold 16,353 shares of company stock worth $41,153. 2.95% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of FOMX. BlackRock Inc. increased its stake in Foamix Pharmaceuticals by 29.7% in the fourth quarter. BlackRock Inc. now owns 620,816 shares of the specialty pharmaceutical company’s stock valued at $2,229,000 after acquiring an additional 142,159 shares during the period. Knott David M grew its stake in Foamix Pharmaceuticals by 68.0% during the first quarter. Knott David M now owns 346,346 shares of the specialty pharmaceutical company’s stock worth $1,299,000 after buying an additional 140,146 shares during the last quarter. IPG Investment Advisors LLC bought a new stake in Foamix Pharmaceuticals during the first quarter worth about $231,000. Delek Group Ltd. bought a new stake in Foamix Pharmaceuticals during the first quarter worth about $189,000. Finally, Handelsbanken Fonder AB grew its stake in Foamix Pharmaceuticals by 6.3% during the first quarter. Handelsbanken Fonder AB now owns 680,000 shares of the specialty pharmaceutical company’s stock worth $2,550,000 after buying an additional 40,000 shares during the last quarter. 55.13% of the stock is currently owned by institutional investors and hedge funds.

Foamix Pharmaceuticals Company Profile

Foamix Pharmaceuticals Ltd., a late clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations for dermatological therapy in the United States, France, Denmark, and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline that has completed third pivotal Phase III clinical trial for the treatment of moderate-to-severe acne; and FMX103, which is in Phase III clinical trial for the treatment of moderate-to-severe papulopustular rosacea.

Recommended Story: Trading on Margin

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Foamix Pharmaceuticals (NASDAQ:FOMX)

Receive News & Ratings for Foamix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.